论文部分内容阅读
目的评价伊立替康联合顺铂方案治疗晚期食管癌的疗效及不良反应。方法经病理学或细胞学确诊的晚期食管癌15例,患者采用伊立替康联合顺铂进行化疗,21d化疗1次为1个周期,2个周期后进行疗效评价,随访24个月。结果 15例患者共完成50个周期化疗,化疗后复查:部分缓解(PR)8例(53.3%),稳定(SD)5例(33.3%),进展(PD)2例(13.3%),有效率(RR)为53.3%,中位疾病进展时间5.2个月,中位生存期10.5个月。主要不良反应为延迟性腹泻和粒细胞减少。结论伊立替康联合顺铂方案治疗晚期食管癌疗效确切,毒性反应较轻,值得临床进一步研究。
Objective To evaluate the efficacy and adverse reactions of irinotecan combined with cisplatin in the treatment of advanced esophageal cancer. Methods Fifteen patients with advanced esophageal cancer diagnosed by pathology or cytology were treated with irinotecan and cisplatin. The chemotherapy was performed once every 21 days for one cycle. The efficacy was evaluated after two cycles and was followed up for 24 months. Results Fifteen patients completed a total of 50 cycles of chemotherapy and were followed up after chemotherapy. Eight patients (53.3%) had partial remission (PR), 5 patients (33.3%) had stable (SD) and 2 patients (13.3%) had PD The efficiency (RR) was 53.3%, the median progression time was 5.2 months, and the median survival time was 10.5 months. The main adverse reactions were delayed diarrhea and neutropenia. Conclusion The combination of irinotecan and cisplatin in the treatment of advanced esophageal cancer has definite curative effect and mild toxicity. It is worth further clinical study.